GS-5894 / Gilead - LARVOL DELTA

Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov) - P1 | N=49 | Completed | Sponsor: Gilead Sciences | Active, not recruiting ➔ Completed | Trial completion date: Mar 2027 ➔ Mar 2024 | Trial primary completion date: Mar 2027 ➔ Mar 2024

Trial completion • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov) - P1 | N=49 | Active, not recruiting | Sponsor: Gilead Sciences | Recruiting ➔ Active, not recruiting | N=110 ➔ 49 | Trial completion date: Dec 2024 ➔ Mar 2027 | Trial primary completion date: Dec 2024 ➔ Mar 2027

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Gilead Sciences | Trial completion date: May 2024 ➔ Dec 2024 | Trial primary completion date: May 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4

Preclinical Characterization of GS-5894, a Potent NNRTI With Once-Weekly Oral Dosing Potential (CROI 2024) - "GS-5894 is a novel and potent NNRTI with an improved resistance profile compared to other NNRTIs. Given the high plasma binding and low predicted metabolic clearance, GS-5894 has the potential for once-weekly oral dosing in PWH for the treatment of HIV-1 infection."

Preclinical • Human Immunodeficiency Virus • Infectious Disease • CD4

Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Gilead Sciences | Phase classification: P1b ➔ P1

Phase classification • Human Immunodeficiency Virus • Infectious Disease • CD4

Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov) - P1b | N=110 | Recruiting | Sponsor: Gilead Sciences | Not yet recruiting ➔ Recruiting

Enrollment open • Human Immunodeficiency Virus • Infectious Disease • CD4

Study of Novel Antiretrovirals in Participants With HIV-1 (clinicaltrials.gov) - P1b | N=110 | Not yet recruiting | Sponsor: Gilead Sciences

New P1 trial • Human Immunodeficiency Virus • Infectious Disease • CD4